

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

**VOLUNTARY ANNOUNCEMENT
FIRST PATIENT TREATMENT IN MULTI-CENTER
REGISTRATION CLINICAL TRIAL OF ReachTactile™
ROBOTIC-ASSISTED TAVR SYSTEM**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has enrolled the first patient in the multi-center registration clinical trial for the ReachTactile™ robotic-assisted Transcatheter Aortic Valve Replacement (“**TAVR**”) system (the “**System**”). On September 17, 2025, Academician Yaling Han’s team at General Hospital of Northern Theater Command successfully completed the first patient treatment, utilizing the ReachTactile™ robotic-assisted TAVR system to implant a TaurusElite® transcatheter aortic valve in a patient with severe aortic stenosis. This registration clinical trial of the System is a prospective, multi-center, randomized controlled, non-inferiority study. It is designed to assess the safety and efficacy of ReachTactile™ robotic-assisted TAVR system and its single-use kit in TAVR procedures. The trial results will be included in the Company’s future registration application to the National Medical Products Administration.

ReachTactile™ is a robotic-assisted TAVR system developed internally by the Company that provides an innovative, cost-effective solution for TAVR therapy. Its mobile, modular design fits conventional catheter rooms which allows a single cardiologist to operate multiple devices with sub-millimeter precision. The System features a force-sensing mechanism that provides real-time tactile feedback, to aid navigation in complex vascular conditions. The Master Unit-Slave Unit architecture allows cardiologists to reduce radiation exposure and other occupational diseases, while remote control capabilities via ethernet enable long-distance operations and training.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET THE ReachTactile™ ROBOTIC-ASSISTED TAVR SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, September 26, 2025

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP, Mr. Huacheng WEI as independent non-executive Directors.